Angeli et al
1
recently published a meta-analysis of the effects of angiotensin-converting enzyme
(ACE) inhibitors versus all other drugs for the prevention of congestive heart failure
in patients with systemic hypertension. For each trial, the authors combined the events
in all non-ACE control groups regardless of the antihypertensive treatments patients
in those groups received and compared this event rate with the event rate in the ACE
inhibitor arm. Then, they calculated a pooled estimate of the effects of ACE inhibitors
versus all other antihypertensive agents. This procedure assumes that all other agents
are equal compared with ACE inhibitors. In other words, that they are all uniformly
better, worse, or no different than ACE inhibitors.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension.Am J Cardiol. 2004; 93: 240-243
Article info
Identification
Copyright
© 2004 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
